Integration of Calcium and Cyclic AMP Signaling Pathways by 14-3-3

CHI-WING CHOW AND ROGER J. DAVIS

Howard Hughes Medical Institute and Program in Molecular Medicine, Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605

Received 21 April 1999/Accepted 13 October 1999

Calcium-stimulated nuclear factor of activated T cells (NFAT) transcription activity at the interleukin-2 promoter is negatively regulated by cyclic AMP (cAMP). This effect of cAMP is mediated, in part, by protein kinase A phosphorylation of NFAT. The mechanism of regulation involves the creation of a phosphorylation-dependent binding site for 14-3-3. Decreased NFAT phosphorylation caused by the calcium-stimulated phosphatase calcineurin, or mutation of the PKA phosphorylation sites, disrupted 14-3-3 binding and increased NFAT transcription activity. In contrast, NFAT phosphorylation caused by cAMP increased 14-3-3 binding and reduced NFAT transcription activity. The regulated interaction between NFAT and 14-3-3 provides a mechanism for the integration of calcium and cAMP signaling pathways.

Nuclear factor of activated T cells (NFAT) represents a group of transcription factors that are implicated in the expression of Fas ligand and several cytokine genes, including those encoding interleukin 2 (IL-2), IL-4, and tumor necrosis factor alpha (18, 37, 47, 70). Four members of the NFAT group (NFAT1/NFAT2/NFATp, NFAT2/NFATC1/NFATc, NFAT3, and NFAT4/NFATC3) have been identified, and multiple alternatively spliced isoforms have been described (25, 27, 45, 48, 56). Recent studies have confirmed that NFAT plays a critical role in the expression of IL-2 and IL-4 by T cells (12, 18, 26, 77). However, roles for NFAT in other biological processes have also been reported. For example, NFAT4 is required for normal thymocyte development (57), NFATc participates in heart valve development during embryogenesis (16, 61), NFAT3 interacts with GATA4 and induces heart hypertrophy (50), and NFAT activity controls gene expression in different skeletal muscle fiber types (1, 11).

NFAT is present in the cytoplasm of resting cells (reviewed in references 15 and 62). Upon T-cell activation, a sustained increase in intracellular calcium activates the phosphatase calcineurin (72). Calcineurin binds to a docking site in the NH2-terminal region of NFAT (3), dephosphorylates phosphoserine residues located in the NFAT homology domain, and induces translocation of NFAT from the cytoplasm into the nucleus (14, 29, 68). Recently, several protein kinases that phosphorylate sites located in the NFAT homology domain have been identified; these include glycogen synthase kinase 3, casein kinase 1α, and c-Jun N-terminal kinase (5, 13, 83). The nuclear localization of NFAT is therefore regulated by the opposing actions of protein kinases and the phosphatase calcineurin.

NFAT was identified as the molecular target for cyclosporin A (CsA), an immunosuppressive drug that has allowed important advances in transplantation surgery (20, 66). CsA inhibits calcineurin activity and thus blocks nuclear translocation of NFAT, and consequently IL-2 secretion, by activated T cells (14). In addition, stimuli that activate protein kinase A (PKA), including prostaglandin E2, histamine, epinephrine, and immunosuppressive retroviral peptides, inhibit IL-2 gene expression (22, 31, 75). Conversely, suppression of cyclic AMP (cAMP) signaling is required for T-cell activation (39). The mechanism of inhibition appears to be mediated by the transcriptional induction of phosphodiesterase 7 following T-cell costimulation. Increased phosphodiesterase 7 expression is associated with decreased levels of cAMP and increased IL-2 production (39). Thus, the cAMP signaling pathway represents a physiologically relevant regulatory mechanism that controls IL-2 expression by T cells.

The mechanism by which cAMP regulates IL-2 gene expression has not been clearly defined. It is likely that the effects of cAMP are mediated by activation of PKA since transcription studies demonstrate that the expression of the PKA catalytic subunit suppresses IL-2 promoter activity. Several potential targets of PKA signaling have been identified. For example, cAMP inhibits T-cell receptor tyrosine phosphorylation and down-regulates c-Jun N-terminal kinase activity (28, 58). In addition, several transcription factors, including inducible cyclic AMP early repressor (ICER) (6), NF-κB (54), and NFAT, have been identified as potential mediators of negative regulation by cAMP (reviewed in reference 62). Interestingly, overexpression of NFAT antagonizes the inhibitory effect of PKA on IL-2 gene expression (73). Together, these actions of PKA appear to inhibit IL-2 expression. Nevertheless, the mechanisms that account for the effect of PKA remain unclear.

The purpose of this study was to examine the effect of PKA on negative regulation of NFAT-mediated signal transduction. We show that PKA phosphorylates NFAT and inhibits NFAT transcription activity. Mutational analysis demonstrated that these sites of NFAT phosphorylation by PKA are required for regulation of NFAT transcription activity. NFAT phosphorylation by PKA creates binding sites for 14-3-3. We propose that the PKA-regulated formation of NFAT–14-3-3 complexes may, in part, mediate the effects of cAMP on NFAT transcription activity.

MATERIALS AND METHODS

Cell culture and reagents. BHK fibroblasts, Jurkat T cells, and COS cells were cultured in minimal essential medium, RPMI 1640, and Dulbecco modified Eagle medium, respectively, supplemented with 10% fetal calf serum, 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 μg/ml) (Life Technologies Inc.). BHK and COS cells were transfected by using Lipofectamine (Life Technologies). Ionomycin, phosphorol myristate acetate, dibutylryl cAMP, cal-

* Corresponding author. Mailing address: Howard Hughes Medical Institute, Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation St., Worcester, MA 01605. Phone: (508) 856-6054. Fax: (508) 856-3210. E-mail: Roger.Davis@Ummed. Edu.
NFAT INTERACTION WITH 14-3-3

RESULTS

Phosphorylation by PKA inhibits NFAT transcription activity. NFAT is implicated as an effector molecule that mediates the negative regulatory action of PKA on IL-2 gene expression. We tested whether NFAT is a substrate for PKA (Fig. 1A). In vitro protein kinase assays using purified PKA catalytic subunit demonstrated that NFAT3 is phosphorylated by PKA (Fig. 1A). Deletion analysis identified the NH2-terminal region of NFAT3 as a substrate for PKA. Sequence analysis indicated that there are several potential PKA phosphorylation sites in this region: Ser-264, Ser-272, Ser-273, and Ser-289 (Fig. 1A). These Ser residues are conserved in other members of the NFAT group (Fig. 1A). We performed site-directed mutagenesis to replace these potential phosphorylation sites with Ala, creating [Ala272,273,274] NFAT. Mutation at Ser-272, Ser-273, and Ser-274 reduced PKA phosphorylation of NFAT3 (Fig. 1A). A similar reduction in PKA phosphorylation was caused by mutation at Ser-289 (Fig. 1A). In contrast, replacement of Ser-272, Ser-273, Ser-274, and Ser-289 with Ala eliminated phosphorylation of NFAT3 by PKA (Fig. 1A). This observation indicated that Ser-272 was not phosphorylated by PKA. Control experiments demonstrated that phosphorylation by CREB by PKA in the same assay was not affected by these NFAT3 mutations (data not shown). Together, these data demonstrate that the PKA sites on NFAT3 are phosphorylated in vitro.

Dephosphorylation of NFAT causes increased electrophoretic mobility during SDS-PAGE (15, 62). We therefore examined the electrophoretic mobility of wild-type and mutated [Ala272,273,274,289] NFAT3. Immunoblot analysis demonstrated that the mutated [Ala272,273,274,289] NFAT3 exhibited increased electrophoretic mobility compared to wild-type NFAT3 (Fig. 1B). Activated calcineurin dephosphorylated both wild-type and mutated [Ala272,273,274,289] NFAT3. Importantly, dephosphorylated wild-type and mutated [Ala272,273,274,289] NFAT3 showed similar electrophoretic mobilities (Fig. 1B). These data suggest that the PKA sites contribute to the phosphorylation of NFAT3 in vivo. To test this hypothesis directly, we examined in vivo phosphorylation of NFAT3 in cells labeled with [32P]phosphate (Fig. 1C). Tryptic phosphopeptide mapping demonstrated that coexpression of the PKA catalytic subunit increased the number of phosphopeptides in wild-type NFAT3 (arrowheads in Fig. 1C). These PKA-dependent phosphopeptides were absent in maps of the mutated [Ala272,273,274,289] NFAT3 that was not phosphorylated by PKA in vitro. Together, these data establish that NFAT3 is phosphorylated in vivo and in vitro by PKA.

Replacement of Ser-272, Ser-273, Ser-274, and Ser-289 of NFAT3 eliminated phosphorylation by PKA in vitro (Fig. 1A). Interestingly, Ser-272 and Ser-289 are conserved in other members of the NFAT group of transcription factors (Fig. 1A). We therefore postulated that Ser-272 and Ser-289 might represent the sites of NFAT3 phosphorylation by PKA. To test this hypothesis, we tested the effect of the replacement of Ser-272 and Ser-289 with Ala residues. Mutation at Ser-272 and Ser-289 was sufficient to prevent phosphorylation of NFAT3 by PKA (Fig. 1D). These data indicate that Ser-272 and Ser-289 are phosphorylated by PKA. To test whether these sites are phosphorylated in vivo, we examined the effect of individual point mutations at each of these sites on NFAT3 phosphorylation (Fig. 1D). Phosphopeptide mapping demonstrated that mutations at Ser-273 and Ser-274 did not cause marked changes in NFAT3 phosphorylation in vivo. In contrast, mutations at Ser-272 and Ser-289 caused the loss of phosphopeptides (arrowheads in Fig. 1D). These phosphopeptides correspond to peptides observed in maps of NFAT3 phosphorylated by PKA in vitro. Together, these data demonstrate that Ser-272 and Ser-289 represent the major sites of NFAT3 phosphorylation by PKA in vivo and in vitro (Fig. 1D).

To test the effect of PKA phosphorylation on NFAT function, we examined the transcription activity of wild-type and phosphorylation-defective NFAT3. Transcription activity was measured by using an NFAT-luciferase reporter plasmid containing three copies of an NFAT–AP-1 composite element derived from the IL-2 promoter. Both wild-type and mutated NFAT3 caused increased reporter gene expression (Fig. 1E).
FIG. 1. Phosphorylation by PKA inhibits NFAT transcription activity. (A) Mutational analysis of NFAT3 phosphorylation by PKA. The primary sequence of the NFAT homology domain of NFAT3 is compared with sequences of NFATp (NFAT1), NFATc (NFAT2), and NFAT4 (upper panel). Potential PKA phosphorylation sites are highlighted with filled boxes. NLS-1 and the conserved SP box C are indicated. Recombinant NFAT3 (1 μg) was phosphorylated by purified PKA catalytic subunit in the presence of [γ-32P]ATP (middle panel; sizes are indicated in kilodaltons). Phosphorylated NFAT3 was detected by autoradiography and quantitated by PhosphorImager analysis (lower panel). (B) Replacement of Ser 272, Ser 273, Ser 274, and Ser 289 with Ala increases the electrophoretic mobility of NFAT3 during SDS-PAGE. Epitope-tagged wild-type and mutated [Ala 272,273,274,289] NFAT3 were expressed in COS cells without (Control) and with activated calcineurin (ΔCN). NFAT3 proteins were detected in immunoblot analysis by using monoclonal antibody M2. (C) NFAT3 is phosphorylated by PKA in vivo. Epitope-tagged wild-type and mutated [Ala272,273,274,289] NFAT3 were expressed in COS cells without (Control) and with PKA. The cells were labeled with [32P]phosphate, and the NFAT3 proteins were isolated by immunoprecipitation. The phosphorylation of NFAT3 was examined by tryptic phosphopeptide mapping. (D) PKA phosphorylates NFAT3 on Ser272 and Ser289 in vivo and in vitro. Recombinant NFAT3 (1 μg) was phosphorylated by purified PKA in the presence of [γ-32P]ATP (upper left panel). The effect of replacement of Ser272 and Ser289 with Ala was examined. The in vitro phosphorylated wild-type NFAT3 was examined by tryptic phosphopeptide mapping (upper right panel).
Treatment of the cells with dibutyryl cAMP or coexpression of PKA catalytic subunit caused inhibition of transcription activity mediated by wild-type NFAT3 (Fig. 1F). In contrast, transcription activity mediated by the mutated phosphorylation-defective NFAT3 was not inhibited under these conditions (Fig. 1F). These data suggest that PKA down-regulates NFAT transcription activity by a mechanism that requires NFAT phosphorylation.
Phosphorylation is an important mechanism that regulates the subcellular distribution of NFAT (15, 62). Two functionally redundant nuclear localization sequences (NLS) in NFAT have been identified (4, 44). These correspond to NFAT3 residues 268 to 270 (NLS-1) and 672 to 675 (NLS-2) (Fig. 1F). Intramolecular interaction with phosphoserine residues located in the NFAT NH$_2$ terminus may control the function of NLS-2 (5). However, the mechanism that regulates NLS-1 is unclear. Interestingly, sites of PKA phosphorylation are located adjacent to NLS-1. To test whether phosphorylation at these sites alters NLS-1 function, we examined the effect of PKA on the subcellular distribution of a truncated NFAT molecule (residues 1 to 580) that contains NLS-1, but not NLS-2, by immunofluorescence analysis (Fig. 1G). The truncated NFAT3 molecule was found in the cytosol, and this localization was not affected by PKA (Fig. 1G). Activated calcineurin induced NFAT3 nuclear accumulation, which was blocked by PKA (Fig. 1G). Replacement of the PKA phosphorylation sites with Ala residues eliminated the effect of PKA to oppose calcineurin-stimulated nuclear accumulation (Fig. 1G). These data indicate that PKA phosphorylation may regulate the function of NLS-1.

Both NLS-1 and NLS-2 are implicated in the mechanism of NFAT nuclear accumulation (4, 44). To test whether PKA was able to regulate NFAT subcellular distribution we used full-length NFAT3, which contains both NLS-1 and NLS-2. Immunofluorescence analysis demonstrated that both wild-type and mutated phosphorylation-defective NFAT3 were located in the cytosol (Fig. 1G). Calcineurin-stimulated nuclear accumulation was observed in experiments using both wild-type and mutated phosphorylation-defective NFAT3 (Fig. 1G). No effect of PKA on the subcellular distribution of these NFAT3 molecules was observed (Fig. 1G). Together, these data indicate that while PKA may regulate the function of NLS-1, PKA signaling was not sufficient to alter the nuclear accumulation of wild-type NFAT. This is probably because PKA does not regulate NLS-2. PKA can therefore inhibit NFAT transcription activity independently of changes in the subcellular distribution of NFAT. Electrophoretic mobility shift assays indicated that treatment with dibutyryl cAMP did not inhibit NFAT DNA binding activity (data not shown). Thus, PKA may exert a direct action on NFAT transcription activity. This effect of PKA requires the sites of NFAT phosphorylation by PKA.

Phosphorylation-dependent interaction of NFAT with 14-3-3. The sites of PKA phosphorylation are located within the conserved NFAT homology region (Fig. 1A). This region is postulated to form a complex subdomain upon phosphorylation that masks important NFAT regulatory elements, such as NLS-1 (62). Formation of this subdomain may involve both intra- and intermolecular interactions. To test whether PKA phosphorylation altered intermolecular interactions, we used NFAT as an affinity matrix to purify molecules that bind the conserved NFAT homology region (Fig. 1A). This region is conserved NFAT homology region. Two proteins (30 and 60 kDa) were found to bind GST-NFAT3 but not GST (Fig. 2A). The 60-kDa protein may correspond to the catalytic subunit of calcineurin, which is known to bind to the NFAT homology domain (3, 21). Indeed, immunoblot analysis confirmed that calcineurin bound to GST-NFAT3 (data not shown). In contrast, the identity of the 30-kDa protein that bound NFAT3 was unclear. We suspected that this 30-kDa protein might be 14-3-3 because of the similar mass and the reported function of 14-3-3 as a phosphoprotein ligand (53). To test this hypothesis, we performed immunoblot analysis using an antibody to 14-3-3. These experiments demonstrated that the NH$_2$-terminal region of NFAT3 bound 14-3-3 (Fig. 2B).

NFAT was first characterized as a transcription factor in T

FIG. 2. NFAT interacts with 14-3-3. (A) Immobilized GST and GST-NFAT3 (residues 1 to 308) were incubated with extracts prepared from [35S]methionine-labeled BHK cells. Bound proteins were separated by SDS-PAGE and detected by autoradiography. (B) Recombinant GST and GST-NFAT3 (residues 1 to 308) were phosphorylated by incubation with 1 mM ATP and purified PKA catalytic subunit. Immobilized GST and GST-NFAT3 were incubated with extracts prepared from Jurkat T cells. Bound 14-3-3 was detected by immunoblot (IB) analysis. The GST and GST-NFAT3 fusion proteins were detected by staining with Coomassie blue. (C) NFATp interacts with 14-3-3 in vivo. NFATp was immunoprecipitated from Jurkat T cell extracts by using a rabbit antibody to NFATp. Preimmune antibody was used as a control. 14-3-3 in the immunoprecipitates (IP) was detected by immunoblot (IB) analysis. (D) NFAT proteins bind 14-3-3. NFAT3, NFAT4, NFATp and NFATc were expressed in COS cells. NFATp was immunoprecipitated with an antibody to NFATp. Epirote-tagged NFAT3, NFAT4, and NFATc were immunoprecipitated with the anti-Flag monoclonal antibody (Ab) M2. 14-3-3 in the cells lysate and in the immunoprecipitates (IP) was detected by immunoblot (IB) analysis. Extracts prepared from mock-transfected cells were used as a control. IgG, immunoglobulin G.
cells (67). We therefore examined the interaction of endoge-
nous NFAT with 14-3-3 in T cells by coimmunoprecipitation 
analysis. Jurkat T cells, which express predominantly the 
NFATp isoform, were used for these assays. Immunoblot anal-
ysis demonstrated the presence of 14-3-3 in NFATp immuno-
precipitates (Fig. 2C). These data confirm the conclusion that 
NFAT interacts with 14-3-3. Since the NH$_2$-terminal region of 
NFAT3 is conserved in the NFAT group of transcription fac-
tors, we also examined whether other members of the NFAT 
group interacted with 14-3-3. Coimmunoprecipitation assays 
demonstrated that 14-3-3 was detected in NFAT3, NFAT4, 
NFATp, and NFATc immunoprecipitates (Fig. 2D). These 
data indicate that interaction with 14-3-3 is a common property 
of NFAT transcription factors.

**PKA phosphorylation sites mediate the interaction of NFAT with 14-3-3.** To delineate the 14-3-3 binding site on NFAT, we 
examined the interaction between various NFAT3 deletion 
mutants and 14-3-3. Immunoblot analysis demonstrated similar 
levels of expression of the NFAT proteins (Fig. 3A). The inter-
action between 14-3-3 and Raf-1 was not affected by the various 
NFAT3 proteins (Fig. 3A). In contrast, deletion of 
NFAT3 sequences caused marked changes in the binding of 
NFAT3 to 14-3-3. Progressive COOH-terminal truncations of 
NFAT3 demonstrated that the Rel domain was not required 
for 14-3-3 binding. Further deletion to remove the NFAT 
homology domain abolished the interaction with 14-3-3 (Fig. 
3A). A fragment of the NFAT homology domain (NFAT3 
residues 260 to 308) encompassed the major binding sites for 
14-3-3. This region includes the sites of PKA phosphoryla-
tion on NFAT3. We tested whether these phosphorylation sites are 
relevant to the interaction of NFAT3 with 14-3-3. Coinmu-
noprecipitation assays demonstrated that replacement of the 
PKA phosphorylation sites with Ala markedly reduced the 
coimmunoprecipitation of NFAT with 14-3-3 (Fig. 3B). These 
data indicate that the PKA phosphorylation sites of NFAT3 
are important for the interaction with 14-3-3. To quantitate the 
contribution of the PKA phosphorylation sites to 14-3-3 bind-
ing, we examined the interaction of in vitro-translated [35S]me-
thionine-labeled NFAT3 to recombinant 14-3-3. We found 
that wild-type NFAT3 bound to 14-3-3 approximately five 
times as strongly as the mutated phosphorylation-defective 
NFAT3 (Fig. 3C).

Phosphorylation of NFAT3 by PKA increased 14-3-3 bind-
ing in vitro (Fig. 2B). We therefore tested whether PKA in-
creased the binding of 14-3-3 to the mutated phosphorylation-
defective NFAT3. Coexpression of the PKA catalytic subunit 
with wild-type NFAT3 increased 14-3-3 binding (Fig. 3D). Re-
placement of the PKA phosphorylation sites with Ala mark-
edly reduced 14-3-3 binding. Importantly, coexpression of the 
PKA catalytic subunit did not increase 14-3-3 binding to the 
phosphorylation-defective NFAT3. These data indicate that 
the PKA phosphorylation sites on NFAT3 are required for the 
PKA-stimulated interaction of NFAT3 with 14-3-3.

The binding of 14-3-3 can be phosphorylation dependent 
(53, 79). We therefore examined whether phosphorylation con-
tributes to the interaction of NFAT with 14-3-3. NFAT3 pre-
pared by in vitro translation binds to 14-3-3 (Fig. 3C), suggest-
ing either that phosphorylation is not required or that the 
translated NFAT3 is phosphorylated in the reticulocyte lysate. 
To test the latter hypothesis, we investigated the effect of the 
protein kinase inhibitor H7. Similar amounts of in vitro-trans-
lated NFAT3 were obtained in the absence and presence of H7 
(Fig. 4A). However, the presence of H7 during in vitro trans-
lation caused a marked dose-dependent inhibition of NFAT3 
binding to 14-3-3 (Fig. 4A). Similarly, treatment of in vitro-
translated NFAT3 with the phosphatase calcineurin caused 

inhibition of NFAT3 binding to 14-3-3 (Fig. 4B). This effect of 
calcineurin was blocked by a specific peptide inhibitor of cal-
cineurin activity. These data indicate that phosphorylation in-
creases NFAT interaction with 14-3-3. This conclusion was 
confirmed by the observation that NFAT3 phosphorylation by 
PKA increases binding to 14-3-3 both in vitro (Fig. 2A) and in 
vivo (Fig. 3D).

To test whether 14-3-3 can mediate the inhibitory effect of 
PKA phosphorylation on NFAT transcription activity, we in-
vestigated the effect of 14-3-3 overexpression. Since 14-3-3 is 
an abundant cellular protein, a marked effect of ectopic 14-3-3 
expression was not anticipated. However, the expression of 
14-3-3r did cause a moderate (30%) reduction of the transcrip-
tion activity of wild-type NFAT3 but not the mutated phos-
phorylation-defective NFAT3 that lacks PKA phosphorylation 
sites (data not shown). These data are consistent with the 
hypothesis that 14-3-3 binding might mediate the effect of PKA 
on NFAT3 activity.

**Regulation of NFAT binding to 14-3-3 by cAMP and calcium.** The ability of calcineurin to inhibit NFAT binding to 
14-3-3 (Fig. 4B) suggests that calcium signaling may be a 
negative regulator of the interaction between NFAT and 14-3-3. 
In contrast, PKA appears to be a positive regulator of NFAT 
binding to 14-3-3 (Fig. 3D). The opposite effects of calcium 
and cAMP on NFAT–14-3-3 complexes suggests that these 
signaling pathways may have an antagonistic relationship 
in vivo. To test this hypothesis, we examined the effect of calcium 
and cAMP on the formation of endogenous NFATp–14-3-3 
complexes in Jurkat T cells (Fig. 5A). Dibutyryl cAMP and 
ionomycin were used to activate the PKA and calcium signal-
and pathways, respectively. Coimmunoprecipitation assays 
demonstrated that 14-3-3 coprecipitated with NFATp. Treat-
ment with ionomycin caused a marked reduction in NFATp– 
14-3-3 complex formation. The effect of ionomycin was atten-
uated by treatment of the cells with dibutyryl cAMP (Fig. 5A). 
Control experiments demonstrated that calcium and cAMP did 
not affect the binding of Raf-1 to 14-3-3 (data not shown). 
These data indicate that the cAMP signaling pathway can 
anagonize the effect of calcium on NFATp–14-3-3 complex 
formation.

The ability of ionomycin to inhibit NFATp–14-3-3 complex 
formation was further examined in in vitro binding assays (Fig. 
5B). Western blot analysis of extracts prepared from Jurkat T 
cells demonstrated that ionomycin caused a marked increase in 
the electrophoretic mobility of NFATp during SDS-PAGE. 
This increased mobility has been reported to be caused by 
calcineurin-mediated dephosphorylation (15, 62). Binding as-
says demonstrated that ionomycin treatment of Jurkat cells 
inhibited the interaction of NFATp with 14-3-3 in vitro (Fig. 
5B). This ability of ionomycin to increase the electrophoretic 
 mobility of NFATp and to inhibit binding to 14-3-3 was 
blocked if the cells were incubated with the immunosuppres-
sive drug CsA, which inhibits the phosphatase activity of cal-
cineurin (Fig. 5B). The effect of ionomycin on NFATp–14-3-3 
binding was also inhibited when the Jurkat T cells were incu-
bated with dibutyryl cAMP (Fig. 5C). Control experiments 
demonstrated that dibutyryl cAMP and ionomycin did not alter 
the interaction of 14-3-3 with the Raf-1 protein kinase. In 
contrast to CsA, dibutyryl cAMP did not cause a marked de-
crease in NFATp electrophoretic mobility (Fig. 5C). These 
data indicate that calcineurin inhibition does not mediate the 
effect of dibutyryl cAMP. In contrast, these data are consistent 
with the hypothesis that the phosphorylation of NFATp on a 
limited number of sites accounts for the regulation of NFATp/ 
14-3-3 complex formation by the cAMP signaling pathway.
DISCUSSION

14-3-3 was first described as a dimeric protein in the brain (51). Subsequent studies demonstrated that 14-3-3 includes a group of proteins that are highly conserved and ubiquitously expressed (reviewed in references 2 and 63). The general mechanism of action of 14-3-3 proteins appears to involve the formation of complexes with target proteins. In some instances, such complexes depend on the phosphorylation of the 14-3-3 binding partner. A general consensus sequence that mediates phosphorylation-dependent binding to 14-3-3 has been defined as RSXSpXP (53, 79). Nevertheless, other sequences containing phosphoserine have been shown to bind 14-3-3 (17, 36, 42, 81). Structural studies demonstrate the presence of a basic pocket within a conserved groove in 14-3-3 (40, 80).
The binding of 14-3-3 to the phosphorylation sites of NFAT correlates with signaling by calcineurin. Thus, cAMP signaling may act dominantly with respect to signaling by calcineurin.

The sites of phosphorylation-dependent binding of 14-3-3 to NFAT correspond to PKA sites located in the NH₂-terminal region of NFAT. These sites are located immediately adjacent to NLS-1 of NFAT. It is therefore likely that the binding of 14-3-3 to NFAT would cause sequestration and inactivation of NLS-1. This might cause redistribution of NFAT from the nucleus to the cytoplasm and therefore inhibition of NFAT-mediated transcription. The mechanism of nuclear export may include sequestration of NLS-1, but it is also possible that other processes are involved. Several possible mechanisms have been established in previous studies. For example, the yeast transcription factor Pho4 interacts in a phosphorylation-dependent manner with the nuclear export receptor Msn5 (30, 35). A second example is provided by the observation that 14-3-3 proteins contain a conserved nuclear export signal (NES) that may mediate CRM1-dependent translocation of 14-3-3 from the nucleus to the cytoplasm (9, 43). Thus, the binding of 14-3-3 to NFAT may cause both the sequestration of NLS-1 and the attachment of an NES. The NES of 14-3-3 may augment the action of an NES present in the NFAT NH₂-terminal region that allows rapid CRM1-dependent nuclear export (32, 33, 82).

Sequestration of NFAT NLS-1 by an NES-bearing 14-3-3 protein provides an extremely elegant mechanism by which 14-3-3 could regulate the subcellular localization of NFAT transcription factors and thereby inhibit NFAT transcription activity. Indeed, some evidence for this potential mechanism was obtained. Studies of a truncated NFAT3 molecule (residues 1 to 580) that contains NLS-1 but not NLS-2 demonstrated that calcineurin-induced nuclear translocation of activated calcineurin. Thus, cAMP signaling may act dominantly with respect to signaling by calcineurin.
NFAT was opposed by PKA and that this effect of PKA was blocked by mutation of the NFAT phosphorylation sites. However, full-length NFAT3, which contains both NLS-1 and NLS-2, exhibited calcineurin-induced nuclear translocation that was not inhibited by PKA. These data indicate that while 14-3-3 has the potential to regulate the subcellular distribution of NFAT, 14-3-3 by itself was insufficient to cause redistribution of nuclear NFAT to the cytoplasm. It is known that the mode of 14-3-3 binding to phosphoproteins may influence the function of the 14-3-3 NES (64). Thus, the difference observed between the regulation of the full-length and truncated NFAT3 molecules may reflect a difference in the mode of 14-3-3 binding to these phosphoproteins.

The observation that PKA does not alter the subcellular distribution of full-length NFAT indicates that export of NFAT from the nucleus does not account for the effect of PKA to inhibit NFAT transcription activity at the IL-2 promoter. Furthermore, we did not detect PKA-stimulated changes in NFAT DNA binding activity. It is therefore possible that PKA exerts a more direct effect on NFAT transcription activity and that the formation of NFAT complexes with 14-3-3 contributes to the altered function of NFAT following PKA activation. It is likely that NFAT function is altered rather than simply inhibited because while PKA inhibits IL-2 expression, PKA causes increased expression of IL-4 and IL-5 (52). The mechanism by which PKA differentially regulates the NFAT-mediated expression of IL-2 compared with IL-4 and IL-5 is unclear. It is possible that the NFAT complex with 14-3-3 contributes to this differential regulation. Evidence in favor of this hypothesis was obtained from the observation that the overexpression of 14-3-3 inhibits transcription activity at the IL-2 promoter but increases transcription activity at the IL-4 promoter (49). The molecular basis for the differential effect of 14-3-3 on NFAT-mediated transcription is unclear. However, we can speculate that NFAT complexes may differentially collaborate with other transcription factors that are relevant to each promoter, including AP-1 at the IL-2 promoter (15, 62), GATA-3 at the IL-5 promoter (69), and c-Maf or JunB at the IL-4 promoter (24, 38).

Specificity of NFAT interaction with 14-3-3. Binding to 14-3-3 was detected in coimmunoprecipitation assays using members of the NFAT group, including NFATp, NFATc, NFAT3, and NFAT4 (Fig. 2D). Interaction with 14-3-3 therefore appears to be a common property of NFAT transcription factors. The 14-3-3 group of proteins includes seven members (2, 63). Some of these 14-3-3 isoforms are expressed selectively in certain tissues. For example, 14-3-3ε is expressed in T cells (55). It is possible that NFAT binds differentially to these 14-3-3 proteins. Preliminary studies designed to investigate 14-3-3 binding specificity indicated that the amount of NFATp binding to 14-3-3ε was approximately five times greater than binding to 14-3-3γ, while an equal amount of Raf-1 was found to bind each 14-3-3 isoform (data not shown). Whether this difference in binding activity in vitro is relevant in vivo is unclear. Further studies will be required to resolve this question. We note that previous studies have not established biochemical differences in the ligand binding properties of 14-3-3 proteins (79). However, such differences are likely since genetically nonredundant functions for specific 14-3-3 genes have been identified in Drosophila (10, 34).

The specificity of NFAT interaction with 14-3-3 is determined, in part, by the requirement of NFAT phosphorylation. The sites of NFAT phosphorylation that contribute to the interaction with 14-3-3 correspond to PKA sites. Indeed, it is likely that PKA is a physiologically relevant protein kinase since dibutylryl cAMP increases NFAT binding to 14-3-3 in calcium-stimulated cells (Fig. 5). However, the sites of PKA phosphorylation may also be phosphorylated by other protein kinases with similar substrate specificity, including calmodulin-dependent protein kinases, PKB, and PKC. Thus, the regulation of NFAT interaction with 14-3-3 may be a site of integration of multiple signaling pathways that ensures correct responses to complex biological stimuli.

ACKNOWLEDGMENTS

We thank A. Altman, T. Hoey, Y.-C. Liu, R. Maurer, A. Rao, and T. Soderling for providing reagents; T. Barrett and M. Sharma for technical assistance; and K. Gemme for administrative assistance.

C.-W. Chow is an Anrhritis Foundation fellow. This work was supported in part by grants CA65861 and CA72200 from the National Cancer Institute. R.J.D. is an Investigator of the Howard Hughes Medical Institute.

REFERENCES

NFAT INTERACTION WITH 14-3-3


